andrew_monaghan_chiltern__jul_2013

Chiltern hires Andrew Monaghan as director

pharmafile | July 25, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing |  CRO, chiltern, monaghan 

Contract research organisation Chiltern has appointed Andrew Monaghan as its director of Global Pharmacovigilance.

Monaghan has more than 30 years’ experience in clinical research and development, most recently as global head of safety operations at Roche Products, UK where he led and managed 500 safety operations staff across many locations.

Sharon Moore, executive vice president, Global Medical and Regulatory Affairs, said: “We are excited to have Andrew join Chiltern’s Pharmacovigilance team. His strong leadership skills and extensive clinical experience will ensure our clients continue to receive customised and efficient safety solutions to meet their specific product and regulatory requirements, whether with investigational or postmarketed products.”

Advertisement

Monaghan who is UK-based, has been responsible for devising strategies related to organisational design, process improvement and the implementation of new technologies, as well as implementation management. 

Related Content

Lilly secures conditional MHRA approval for new blood cancer treatment

Crown Bioscience opens new US model development centre

Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …

From molecule to market and beyond: Uniphar announces extended global commercialization platform

22 October 2024 – Dublin, Ireland – Healthcare services business, Uniphar, has developed its full-service …

Science image

Drug development contracts: can lessons be learned from healthcare delivery?

There is a very good question to ask at the beginning of every project: “What …

The Gateway to Local Adoption Series

Latest content